ABT-418

ABT-418

Identifiers
IUPAC name 3-Methyl-5-[(2S)-1-methylpyrrolidin-2-yl]-1,2-oxazole
CAS Number	147402-53-7 N
PubChem CID	119380
ChemSpider	106627 Y
ChEMBL	CHEMBL274525 Y
Chemical and physical data
Formula	C9H14N2O
Molar mass	166.22
3D model (Jmol)	Interactive image
SMILES CC1=NOC(=C1)[C@@H]2CCCN2C
InChI InChI=1S/C9H14N2O/c1-7-6-9(12-10-7)8-4-3-5-11(8)2/h6,8H,3-5H2,1-2H3/t8-/m0/s1 Y Key:ILLGYRJAYAAAEW-QMMMGPOBSA-N Y
NY (what is this?)

ABT-418 is a drug developed by Abbott, that has nootropic, neuroprotective and anxiolytic effects, and has been researched for treatment of both Alzheimer's disease and ADHD. It acts as an agonist at neural nicotinic acetylcholine receptors, subtype-selective binding with high affinity to the α₄β₂, α₇/5-HT₃, and α₂β₂ nicotinic acetylcholine receptors but not the α3β4 subtype familiar to nicotine. ABT-418 was reasonably effective for both applications and fairly well tolerated, but produced some side effects, principally nausea, and it is unclear whether ABT-418 itself will proceed to clinical development or if another similar drug will be used instead.